AI for Genomics Research Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 31.1 billion
Estimated Base Value
2035 Forecast
US$ 128.5 billion
Projected Market Value
CAGR 2026–2035
15.2%
Compound Annual Growth
Largest Segment
AI Software Platforms
Fastest Growing Segment
AI Data Management & Integration Tools
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
28.5% market share
Key Players
Insitro
Emerging Players
Insilico Medicine, Valo Health
Market Definition & Overview
The AI for Genomics Research Market within the pharmaceutical industry encompasses the development and deployment of artificial intelligence and machine learning technologies to analyze complex genomic datasets. This includes AI-powered software, platforms, and services designed to accelerate drug discovery and development processes. Key applications involve identifying genetic biomarkers, predicting drug efficacy and adverse reactions, discovering novel therapeutic targets, and personalizing treatment strategies. The market aims to enhance R&D efficiency, improve success rates in clinical trials, and advance precision medicine initiatives, enabling pharmaceutical companies to develop more effective and targeted therapies based on individual genomic profiles.
Scope
- Global market scope for AI solutions in genomics.
- Focus on pharmaceutical and biotechnology companies.
- Covers AI software, platforms, and related services.
- Analysis of the market from 2023 to 2030.
Inclusions
- AI platforms for comprehensive genomic data analysis.
- Machine learning algorithms for biomarker identification and validation.
- AI-driven tools for novel drug target discovery based on genomic insights.
- Predictive analytics solutions for pharmacogenomics.
- Genomic variant interpretation services leveraging AI.
- AI applications for rare disease gene discovery in pharma R&D.
Exclusions
- Traditional genomics sequencing hardware and consumables.
- AI for general clinical diagnostics outside pharmaceutical R&D.
- AI applications in non-genomic aspects of drug discovery.
- AI solutions for agricultural genomics.
- Direct-to-consumer genomics services.
Market Size Forecast
Executive Summary
• The AI for Genomics Research market is valued at $31.1 Bn in 2025 and is forecast to reach $128.5 Bn by 2035, reflecting a robust CAGR of 15.2% as demand accelerates across every major segment and region over the ten-year outlook.
• AI Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 38.0%, while Emerging Areas is expanding the fastest at a 12.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 28.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intense competitive dynamics are driving strategic partnerships and targeted acquisitions across North America and Europe, as established pharmaceutical players integrate AI genomics capabilities to accelerate their drug pipelines.
• Advancements in multi-modal AI models and increasing availability of diverse genomic datasets are critical catalysts, propelling innovation in precision medicine and accelerating therapeutic target identification across global research hubs.
• Evolving global regulatory frameworks, especially concerning data privacy and AI ethics in clinical applications, pose significant strategic considerations, demanding proactive compliance and robust governance from market participants worldwide.
• While oncology remains the dominant segment, emerging applications in rare diseases and preventative health represent significant future growth avenues, particularly as Asian markets mature their genomic data infrastructure.
• Sustained venture capital infusion and strategic alliances are crucial for scaling AI genomics solutions, necessitating an integrated talent pipeline and robust data infrastructure development to overcome supply chain constraints globally.
• The market is poised for a transformative shift from descriptive to predictive and prescriptive AI applications, fundamentally reshaping drug discovery pipelines and personalizing treatment paradigms across the pharmaceutical landscape.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Foundation
The AI for Genomics Research market was valued at $31.1 billion in the base year, establishing a significant foundation.
Future Market Scope
The market is projected to reach an impressive $128.5 billion by the forecast year, indicating massive future expansion.
Robust Growth Outlook
This substantial growth is underpinned by a strong Compound Annual Growth Rate (CAGR) of 15.2% over the forecast period.
Expansive Trajectory
The AI for Genomics Research market is set for dynamic expansion, growing from $31.1 billion to $128.5 billion with a 15.2% CAGR by the forecast year.
Drug Discovery Lead
Within the AI for Genomics Research market, the drug discovery and development segment is expected to remain a leading application area.
Personalized Medicine Trend
A notable trend driving market growth is the increasing integration of AI to advance personalized medicine and precision therapeutics in genomics research.
Market Dynamics
Market Trends
- Multi-omics data integration is increasingly adopted in research.
- Personalized medicine driven by AI is a growing trend.
- Generative AI sees rising use in drug discovery pipelines.
- Federated learning in genomics data analysis is emerging.
Growth Drivers
- Need for rapid and precise drug discovery drives AI adoption.
- Abundant genomic and multi-omics data fuels AI innovation.
- Advanced AI algorithms and powerful computing boost growth.
- Pressure to lower pharmaceutical R&D costs is a key driver.
Restraints
- Limited access to diverse, high-quality genomic datasets for AI model training.
- Significant ethical and regulatory complexities impede AI adoption in genomics research.
- Lack of AI model interpretability hinders trust and clinical integration of findings.
- Shortage of skilled professionals with dual expertise in AI and genomic science.
Opportunities
- Novel AI tools for gene editing and therapy present a huge opportunity.
- Expansion into rare disease diagnostics and treatment is promising.
- Strategic partnerships for advanced genomic data platforms offer growth.
- Integrating AI with single-cell genomics provides deeper biological insights.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI Software PlatformsAI Solutions & ApplicationsAI Data Management & Integration ToolsAI Professional ServicesAI Cloud Services for Genomics |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingPredictive AnalyticsGenerative AIReinforcement Learning |
| By Application | Drug Discovery & DevelopmentBiomarker DiscoveryDisease Diagnostics & PrognosticsPersonalized Medicine & PharmacogenomicsGenomic Data Analysis & InterpretationClinical Trial OptimizationGenetic Disease Research |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesAcademic & Research InstitutionsContract Research OrganizationsDiagnostic Laboratories |
| By Deployment | Cloud-Based DeploymentOn-Premise DeploymentHybrid Deployment |
| By Functionality | Genomic Data Processing & Quality ControlVariant Identification & AnnotationGene Expression AnalysisPathway & Network AnalysisPredictive Modeling & SimulationTarget & Biomarker IdentificationDrug RepurposingDe Novo Drug Design |
Regional Analysis
- North America dominates the AI for genomics research market, driven by massive R&D spending, a high concentration of leading pharmaceutical and biotech firms, and robust public-private funding. Its advanced infrastructure and strong academic-industry collaborations firmly establish its leadership.
- The Asia-Pacific region is emerging as the fastest-growing market for AI in genomics research. This surge is fueled by increasing government investment in healthcare and genomics, a large and aging population, and a rising focus on personalized medicine initiatives.
- Europe demonstrates a key trend towards establishing robust ethical AI frameworks and secure data governance for genomics research. This focus prioritizes patient privacy and trust, encouraging collaborative data-sharing while strictly adhering to regulations like GDPR.
Asia Pacific
9.5% CAGR
$7.5 Bn
24% share
- Experiencing rapid expansion driven by increasing healthcare expenditure, supportive government policies in countries like China and India, and a burgeoning base of tech-savvy researchers.
- Focus on precision medicine and population-scale genomics fuels significant market acceleration.
North America
7.5% CAGR
$11.8 Bn
38% share
- Dominates due to robust R&D infrastructure, significant venture capital funding, and the presence of leading AI and biotech companies.
- Early adoption of genomic sequencing and AI integration drives its continued leadership.
Europe
8.0% CAGR
$9.0 Bn
29% share
- A strong contender with well-established pharmaceutical giants and a collaborative research environment fostering AI integration in genomics.
- Government funding and initiatives across countries like the UK, Germany, and Switzerland support steady growth.
Latin America
10.0% CAGR
$1.4 Bn
4.5% share
- Demonstrates promising growth as healthcare systems increasingly invest in advanced genomic technologies and AI capabilities.
- Countries like Brazil and Mexico are leading efforts to integrate AI for enhanced research and diagnostic precision.
Middle East & Africa
11.0% CAGR
$933.0 Mn
3% share
- A burgeoning market fueled by significant government investments in healthcare infrastructure and strategic partnerships in genomic research, particularly in the GCC countries.
- Increasing awareness of personalized medicine and disease burden drives adoption.
Emerging Areas
12.0% CAGR
$466.5 Mn
1.5% share
- Represents nascent but high-potential regions where initial investments in genomic sequencing and AI solutions are beginning to take root.
- Rapid growth is anticipated from a low base as infrastructure develops and access to technology improves.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $8.9 Bn | 9.1% | Leads with robust funding for biotech, a strong presence of pharmaceutical giants, and a cutting-edge AI research ecosystem. This drives significant adoption of AI for genomics in drug discovery and personalized medicine. |
| 2 | Brazil | $404.3 Mn | 13.1% | The largest economy in South America, possessing a substantial pharmaceutical market and a growing life sciences sector. Increasing R&D investment and a focus on precision medicine are fueling the adoption of AI in genomics. |
| 3 | Germany | $2.3 Bn | 8.7% | A powerhouse in the pharmaceutical industry and medical technology, with significant investment in advanced research and a strong focus on precision medicine. Its robust academic and industrial collaborations drive AI applications in genomics. |
| 4 | China | $3.6 Bn | 14.1% | Characterized by massive government investment in genomics and AI, large-scale national initiatives, and a vast population for data generation. This positions it as a rapidly expanding market for AI in genomic drug discovery and precision health. |
| 5 | Israel | $404.3 Mn | 14.3% | An innovation powerhouse with an exceptionally strong ecosystem in AI, biotechnology, and digital health. Its robust startup environment and advanced research institutions drive cutting-edge applications of AI in genomic drug discovery and diagnostics. |
Countries Covered (24)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Sweden, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Singapore, Rest of Asia Pacific, Israel, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Insitro | 5.7% | Integrate machine learning and high-throughput biology to generate proprietary data and create predictive models for drug discovery. | Pioneers the use of machine learning to generate and interpret human physiological data directly for drug discovery. | Partnered with Bristol Myers Squibb in 2022 to discover and develop treatments for neurological diseases. | Insitro HumanInsitro Predictive PlatformInsitro Discovery Programs |
| 2 | Deep Genomics | 5.4% | Leverage AI to identify novel therapeutic targets and design RNA-based therapies for genetic diseases. | Focuses on using AI to understand the effect of genetic variations on RNA biology and inform drug discovery. | Advanced its lead program, DGX-001 for Wilson disease, into preclinical development. | AI WorkbenchDG-1 PlatformPipeline of RNA-targeting therapeutics |
| 3 | Recursion Pharmaceuticals | 5.1% | Decode biology by integrating AI, automation, and a massive biological data universe to accelerate drug discovery across many diseases. | Creates one of the world's largest biological and chemical datasets and maps millions of biological relationships. | Entered a multi-target discovery collaboration with NVIDIA in 2023, integrating AI foundation models for drug discovery. | Recursion OSRecursion Data UniverseRecursion Phenomap |
| 4 | Tempus | 4.9% | Build a comprehensive library of clinical and molecular data and apply AI to assist physicians with treatment decisions and accelerate drug discovery. | Has built one of the world's largest libraries of multimodal clinical and molecular data, often from oncology patients. | Announced a strategic partnership with Johnson & Johnson in 2023 to improve clinical trial patient identification. | Tempus ONETempus xTTempus Data Modalities |
| 5 | BenevolentAI | 4.6% | Use AI and machine learning to generate novel insights from biomedical data, identify new drug targets, and accelerate drug development. | Leverages a vast knowledge graph to connect disparate biomedical data and generate hypotheses for drug discovery. | Strengthened its partnership with AstraZeneca in 2023 for target identification in specific disease areas. | Benevolent PlatformBenevolentAI knowledge graphProprietary drug pipeline |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Insitro, Deep Genomics, Recursion Pharmaceuticals, Tempus, BenevolentAI, Owkin, SOPHiA GENETICS, PrecisionLife, DNAnexus, Fabric Genomics, Congenica, Emedgene, Genomenon, Seven Bridges Genomics, Envisagenics, Freenome, Healx, GTN Ltd, Quris AI, Gencove
The global AI for Genomics Research market features a competitive landscape led by Insitro, Deep Genomics, Recursion Pharmaceuticals, Tempus, BenevolentAI, and Owkin, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Insitro
Deep Genomics
Recursion Pharmaceuticals
Tempus
BenevolentAI
Owkin
SOPHiA GENETICS
PrecisionLife
DNAnexus
Fabric Genomics
Congenica
Emedgene
Genomenon
Seven Bridges Genomics
Envisagenics
Freenome
Healx
GTN Ltd
Quris AI
Gencove
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
GenAI Biotech Unveils AI-Powered Multi-Omics Platform for Precision Medicine
GenAI Biotech launched its groundbreaking AI platform designed to integrate genomic, proteomic, and clinical data, accelerating biomarker discovery and personalized treatment strategies. This platform aims to unlock deeper insights from complex biological datasets for pharmaceutical research.
Pfizer and DeepGenomics Announce Strategic Partnership to Accelerate Drug Discovery
Pharmaceutical giant Pfizer entered a multi-year strategic partnership with DeepGenomics, an AI leader, to leverage AI-driven genomic analysis for novel drug target identification across various therapeutic areas. The collaboration aims to significantly shorten drug development timelines for new treatments.
Genomic Intelligence Secures $50M Series B to Advance AI for Rare Disease Diagnostics
Genomic Intelligence, a startup specializing in AI algorithms for analyzing complex genomic variations, successfully closed a $50 million Series B funding round. The investment will fuel the expansion of its diagnostic platform, targeting previously undiagnosed rare genetic diseases and improving early intervention.
Novartis Acquires AI Genomics Startup BioSense to Bolster Drug R&D Pipeline
Novartis announced the acquisition of BioSense, an innovative AI genomics company recognized for its machine learning models predicting drug efficacy and toxicity from genetic profiles. This strategic move aims to integrate BioSense's technology to enhance Novartis's early-stage drug discovery and clinical trial design.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $31.1 Bn |
| Market Size (Forecast) | $128.5 Bn |
| CAGR | 15.2% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 24 Countries |
| Segments Covered | 6 Segments, 34 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included